← All organizations
Highest phase reached
Phase 3
First clinical trial
Aug 1, 2011First marketed drug
May 1, 2012First NDA
May 1, 2012Last known activity
Apr 30, 2020
Timeline
1990s
- Jun 1, 1993
Target Health Inc.— Founded
2010s
- May 1, 2012
taliglucerase alfa— NDA Organization
Drugs by trial phase (7 distinct, 9 trials)
Phase 3 (3 own, 0 via acquisition)
Phase 2 (3 own, 0 via acquisition)
Other trials (1 own, 0 via acquisition)
Indications
Approved for
Studied for
- Acute Lung Injury
- Bipolar Disorder
- Coronavirus Infections
- Depression
- Depressive Disorder
- Erectile Dysfunction
- Lice Infestations
- Lung Injury
- Mite Infestations
- Parasitic Diseases
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Severe Acute Respiratory Syndrome
- Suicidal Ideation
- Suicide
- Suicide, Attempted
- Syndrome
Marketed drugs (1)
Recent trials (9)
- NCT04311697CollaboratorPhase 2Apr 30, 2020
- NCT03396068CollaboratorPhase 2/Phase 3May 1, 2018
- NCT03396601CollaboratorPhase 3May 1, 2018
- NCT03395392CollaboratorPhase 2/Phase 3Apr 1, 2018
- NCT03402152CollaboratorPhase 2/Phase 3Mar 15, 2018
- NCT02974010CollaboratorPhase 2/Phase 3Jun 15, 2017
- NCT02135549Study directorN/AMay 1, 2014
- NCT01907490CollaboratorPhase 2Mar 1, 2013
- NCT01220206CollaboratorPhase 2Aug 1, 2011
Details
- Founded
- New York, NY, US Jun 1, 1993
- First NDA
- May 1, 2012
- Last known activity
- Apr 30, 2020
Designations held
- Orphan drug
- Fast track
Notes
CRO